Small Molecules
29 September 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress29 September 2019
Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer29 September 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia27 September 2019
Incyte announces positive updated results from phase 2 trial of pemigatinib in patients with previously treated, advanced cholangiocarcinoma27 September 2019
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria27 September 2019
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy27 September 2019
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial27 September 2019
BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors27 September 2019
Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)27 September 2019
CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 201925 September 2019
Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials25 September 2019
Galapagos initiates Phase 1 trial for second Toledo compound25 September 2019
Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS880125 September 2019
OCTIMET Expands Ongoing Proof of Concept Study to Evaluate the Combination of Highly Selective MET Kinase Inhibitor OMO-1 with EGFR TKIs25 September 2019
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis25 September 2019
NORTHSEA THERAPEUTICS: NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)24 September 2019
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma24 September 2019
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 FranchiseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports